<DOC>
	<DOCNO>NCT00148616</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety memantine add-on treatment treatment negative symptomatology cognitive impairment patient chronic schizophrenia . Primary outcome parameter change negative symptom baseline 6 month</brief_summary>
	<brief_title>Memantine Treatment Negative Symptomatology</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Diagnosis schizophrenia ( DSMIV ) Age 18 40 Stable negative syndrome ( PANSS negative score &gt; 20 ) At least one previous schizophrenic episode Informed consent Subjects must consider investigator compliant investigation appointment Subjects must educational level degree understand meaningfully communicate investigator Axis I disorder schizophrenia within 12 month , e.g . schizoaffective disorder Severe positive symptomatology ( PANNS positive score &gt; PANNS negative score ) Dependency alcohol addictive drug within 6 month baseline evaluation Contraindication risperidone Significant neurological , cardiovascular , hepatic , renal , metabolic , medical disease clinically relevant abnormality laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Memantine</keyword>
	<keyword>Negative Syndrome</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognitive impairment</keyword>
</DOC>